# Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Source: https://onco.cc/trials/nct03547973/  
OnCo record `nct03547973` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sacituzumab govitecan, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab and Carboplatin in bladder & urothelial cancer, run by Gilead Sciences, active and no longer recruiting.

## Summary

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread is a phase 2 interventional study registered as NCT03547973 by Gilead Sciences, with 502 participants enrolled, started 2018-08-13 and due to reach its primary completion in 2030-04. Interventions recorded: Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab and Carboplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03547973
- Phase: 2
- Setting: A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
- Sponsor: Gilead Sciences
- Enrolled: 502

## Sources

- ClinicalTrials.gov NCT03547973: https://clinicaltrials.gov/study/NCT03547973

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Avelumab](https://onco.cc/drugs/avelumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct03547973.json